Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (7): 6-12.doi: 10.6040/j.issn.1671-7554.0.2019.191
WANG Jianxiang, GU Runxia
CLC Number:
| [1] Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia [J]. N Engl J Med, 2016, 374(23): 2209-2221. [2] Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia [J]. N Engl J Med, 2012, 366(12): 1079-1089. [3] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [J]. N Engl J Med, 2013, 368(22): 2059-2074. [4] Grimwade D, Mrozek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia [J]. Hematol Oncol Clin North Am, 2011, 25(6): 1135-1161. [5] Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance [J]. Blood, 2016, 127(1): 29-41. [6] Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation [J]. N Engl J Med, 2017, 377(5): 454-464. [7] Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J]. Blood, 2017, 129(4): 424-447. [8] NCCN. NCCN clinical practice guilelines in oncology: acute meyloid leukemia [J]. Version 1, 2019. [9] Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia(SORAML): a multicentre, phase 2, randomised controlled trial [J]. Lancet Oncol, 2015, 16(16): 1691-1699. [10] Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study [J]. Lancet Oncol, 2017, 18(8): 1061-1075. [11] Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor [J]. Proc Natl Acad Sci USA, 2014, 111(14): 5319-5324. [12] Cortes J, Khaled S, Martinelli G, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication-mutated(mut)relapsed/refractory AML in the phase 3, randomized, controlled quantum-r trial [J]. EHA, 2018, LB2600. [13] Pratz K, Cherry M, Altman JK, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia(AML)[J]. Blood, 2017, 130: 722. [14] Walter RB, Collins RH, Stone RM, et al. Addition of crenolanib to standard induction and consolidation therapies improved long-term outcomes in newly diagnosed FLT3 mutant AML patients ed acute myelo[J]. EHA, 2018, 227. [15] Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value [J]. Blood, 2010, 116(12): 2122-2126. [16] Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate[J]. Nature, 2009, 462(7274): 739-744. [17] Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation [J]. Cancer Cell, 2010, 18(6): 553-567. [18] Dinardo CD, Stein EM, Stéphane de Botton, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML [J]. N Engl J Med, 2018, 378(25): 2386-2398. [19] Levine RL, Flinn IW, Kantarjian HM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia [J]. Blood, 2017, 130(6): 722-731. [20] Stein EM, Dinardo CD, Amir T, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions [J]. Blood, 2018, 132: 560. [21] Pan RQ, Hogdal LJ, Benito JM, et al.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia [J]. Cancer Discov, 2014, 4(3): 362-375. [22] Dinardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study [J]. Lancet Oncol, 2018, 19(2): 216-228. [23] 张岩, 汤君宇, 张梅, 等. BCL-2抑制剂联合低剂量阿糖胞苷治疗异基因造血干细胞移植后复发老年急性髓系白血病一例报告并文献复习[J].中华血液学杂志, 2019, 40(2): 144-146. [24] Wei A, Strickland SA, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study [J]. J Clin Oncol, 2019, 37(15): 1277-1284. [25] DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J]. Blood, 2019, 133(1): 7-17 [26] Cortes JE, Heidel FH, Heuser M, et al. A phase 2 randomized study of low dose Ara-C with or without glasdegib(PF-04449913)in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome [J]. Blood, 2016, 128: 99. [27] Minami Y, Minami H, Miyamoto T, et al. Phase I study of glasdegib(PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies [J]. Cancer Sci, 2017, 108(8): 1628-1633. [28] Hassan F, Oumedaly R, Emmanuel R, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association [J]. Am J Hematol, 2015, 87(1): 62-65. [29] Pautas Cécile, Raffoux E, Lambert J, et al. Outcomes following hematopoietic stem cell transplantation in patients treated with chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia [J]. Blood, 2018, 132: 28. [30] Castaigne S, Pautas C, Terr'e C, et al. Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia(ALFA-0701): a randomised, open-label, phase 3 study [J]. Lancet, 2012, 379(9825): 1508-1516. [31] Uy GL, Rettig MP, Vey N, et al. Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific dart? protein in patients with relapsed/refractory acute myeloid leukemia(AML)[J]. Blood, 2018, 132: 764. [32] Friedrich M, Henn A, Raum T, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia [J]. Mol Cancer Ther, 2014, 13(6): 1549-1557. [33] Ravandi F, Stein AS, Kantarjian HM, et al. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager(BiTE)antibody construct, in relapsed/refractory acute myeloid leukemia(R/R AML)[J]. Blood, 2018, 132: 25. [34] Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia(AML): results from the prospective randomized AMLSG 09-09 phase-III study [J]. Blood, 2018, 132: 81. [35] Lynn Q, David MD, Alison K, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib [J]. Nat Med, 2018, 24(8): 1167-1177. [36] Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia [J]. Nature, 2018, 526: 526-531. [37] Daver NG, Pollyea DA, Garcia JS, et al. Safety, Efficacy, Pharmacokinetic(PK)and biomarker analyses of BCL2 inhibitor venetoclax(Ven)plus MDM2 inhibitor idasanutlin(idasa)in patients(pts)with relapsed or Refractory(R/R)AML: a phase Ib, non-randomized, open-label study [J]. Blood, 2018, 132: 767. [38] 米瑞华, 袁芳芳, 魏旭东. 急性髓系白血病免疫治疗新进展[J]. 白血病·淋巴瘤, 2019, 28(1): 12-16. MI Ruihua, YUAN Fangfang, WEI Xudong.Progress of immunotherapy of acute myelogenous leukemia[J]. Journal of Leukemia & Lymphoma, 2019, 28(1):12-16. [39] Jetani H, Cadenas IG, Nerreter T, et al. FLT3 inhibitor treatment increases FLT3 expression that exposes FLT3-ITD+ AML blasts to elimination by FLT3 CAR-T cells [J]. Blood, 2018, 132: 903. [40] Daver NG, Manero GG, Sreyashi Basu S, et al. Safety, efficacy, and biomarkers of response to azacitidine(AZA)with nivolumab(Nivo)and AZA with Nivo and ipilimumab(Ipi)in relapsed/refractory acute myeloid leukemia: a non-randomized, phase 2 study[J]. Blood, 2018, 132: 906. [41] 陈子兴. 急性髓系白血病的表观遗传调控异常和表观基因组景观改变及靶向治疗研究进展[J]. 中华血液学杂志, 2019, 40(1): 78-82. CHEN Zixing. The aberrant epigenetic regulation and epigenomic landscape alteration in human acute myelogenous leukemia and the emerged agents that target epigenetic regulators[J]. Chinese Journal of Hematology, 2019, 40(1):78-82. [42] Rashidi A, Uy GL. Targeting the microenviron-ment in acute myeloid leukemia [J]. Curr Hematol Malig Rep, 2015, 10(2): 126-131. [43] Brunner AM, Blonquist TM, Daniel J, et al. Phase II clinical trial of alisertib, an aurora kinase inhibitor, in combination with induction chemotherapy in high-risk, untreated patients with acute myeloid leukemia [J]. Blood, 2018, 132: 766. [44] Walker AR, Bhatnagar B, Marcondes A, et al. Interim results of a phase 1b/2 Study of entospletinib(GS-9973)monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia [J]. Blood, 2016, 128: 2831. [45] Soliman HH, Minton SE, Han HS, et al. A phase I study of indoximod in patients with advanced malignancies [J]. Oncotarget, 2016, 7(16): 22928-22938. [46] Baker A, Gregory GP, Verbrugge I, et al. The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia [J]. Cancer Res, 2016, 76(5): 1158-1169. |
| [1] | WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117. |
| [2] | Haipeng SI,Wencan ZHANG,Le LI,Xin ZHOU. Research advances on risk factors, diagnosis and treatment of Kümmell's disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 25-32. |
| [3] | ZHANG Xiaohui, LUO Jianmin, SUO Xiaohui, SUN Guofeng, LI Jing. Relationship between methylation of tumor suppressor genes SOCS1 and SOCS3 and remission and prognosis of 80 acute myeloid leukemia patients [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 67-73. |
| [4] | WANG Yan, ZHANG Yuhui, HU Naibo, TENG Guangshuai, ZHOU Yuan, BAI Jie. Characteristics of bone marrow immune microenvironment in patients with acute myeloid leukemia based on single-cell RNA sequencing [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 30-38. |
| [5] | Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41. |
| [6] | Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94. |
| [7] | HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5. |
| [8] | WANG Haitao. Development of precision medicine in the treatment of castration-resistant prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 30-35. |
| [9] | QI Meng, HUANG Yan, WU Shanshan, LIU Bo, ZHANG Siwei. Effects of single-energy metal artifact reduction algorithm: a systematic review and Meta-analysis [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 59-64. |
| [10] | JIANG Baofa, DING Guoyong, LIU Xuena. Research progress on the relationship between floods and human health [J]. Journal of Shandong University (Health Sciences), 2018, 56(8): 21-28. |
| [11] | MA Runmei, ZHANG Yi, WANG Yanwen, XU Dandan, SUN Zhiying, SHI Wanying, CUI Liangliang, LI Tiantian. A systematic review on association between particulate matter and blood glucose [J]. Journal of Shandong University (Health Sciences), 2018, 56(11): 27-33. |
| [12] | WANG Shu, PENG Yuan. Treatment of early breast cancer: more or less? Study from the 2017 American Society of Clinical Oncology Annual Meeting [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 17-21. |
| [13] | CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017 [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16. |
| [14] | ZHAO Zuohui, LI Cuiling, WANG Daoguang, WANG Fengqin, QU Hongyi, DING Sentai, GONG Jing, LÜ Jiaju, YANG Jinghua. Effect of MnSOD acetylation on the proliferation and apoptosis of clear cell renal cell carcinoma cell line 786-O [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 31-35. |
| [15] | DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30. |
|
||
